Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.35 |
| ▸ | APAF1 | O14727 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2241352 | 1.00 | TLR8 (0.35) | TLR8L3MBTL1SOAT1APAF1ALDH1A1 | |
| SCHEMBL13498062 | 0.92 | L3MBTL1 (0.36) | L3MBTL1 | |
| SCHEMBL16327362 | 0.82 | POLB (0.35) | TLR8L3MBTL1APAF1ALDH1A1CYP1A2 | |
| SCHEMBL19366237 | 0.79 | L3MBTL1 (0.49) | TLR8L3MBTL1SOAT1APAF1ALDH1A1 | |
| SCHEMBL10408702 | 0.73 | L3MBTL1 (0.46) | L3MBTL1SOAT1 | |
| SCHEMBL10408681 | 0.73 | L3MBTL1 (0.46) | L3MBTL1SOAT1 | |
| SCHEMBL28016716 | 0.71 | SOAT1 (0.51) | SOAT1 | |
| SCHEMBL1819611 | 0.70 | ALDH1A1 (0.40) | TLR8L3MBTL1SOAT1APAF1ALDH1A1 | |
| SCHEMBL309485 | 0.70 | TLR8 (0.53) | TLR8L3MBTL1APAF1ALDH1A1CYP1A2 | |
| SCHEMBL17921774 | 0.69 | L3MBTL1 (0.52) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372927-B2 | Metal-ligand complexes and catalysts | DOW GLOBAL TECHNOLOGIES, LLC (US) | 2013-02-12 | — | — | US | disclosed |
| US-8202954-B2 | Metal-ligand complexes and catalysts | DOW GLOBAL TECHNOLOGIES LLC | 2012-06-19 | — | — | US | disclosed |
| US-20110207902-A1 | METAL-LIGAND COMPLEXES AND CATALYSTS | DOW GLOBAL TECHNOLOGIES LLC | 2011-08-25 | — | — | US | disclosed |
| US-20100048842-A1 | METAL-LIGAND COMPLEXES AND CATALYSTS | DOW GLOBAL TECHNOLOGIES LLC | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207902-A1 | METAL-LIGAND COMPLEXES AND CATALYSTS | ZC3HAV1L, FARS2, ACSL4 | TLR8 1550/4885L3MBTL1 1091/4885SOAT1 103/4885 |
| US-20100048842-A1 | METAL-LIGAND COMPLEXES AND CATALYSTS | ZC3HAV1L, FARS2, ACSL4 | TLR8 1550/4885L3MBTL1 1091/4885SOAT1 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.